A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

Completed · Phase 2 · Has a placebo group

Conditions studied: Type 2 Diabetes Mellitus, Chronic Kidney Disease

In brief

Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD. Empagliflozin lowers blood sugar levels by increasing the excretion of glucose from the blood into the urine. In this study, the researchers want to learn how well the combination of finerenone and empagliflozin helps to slow down the worsening of the participants' kidney function compared to either treatment alone. For this, the level of protein in the urine will be measured. The investigators also want to know how safe the combination is compared to either treatment alone. Depending on the treatment group, the participants will either take the combination of finerenone and empagliflozin, or finerenone together with a placebo, or empagliflozin together with a placebo, once a day as tablets by mouth. A placebo looks like a treatment but does not have any medicine in it. Importantly, the participants will also continue to take their other current medicine for CKD and T2D. The participants will be in the study for up to 7.5 months and will take the study treatments for 6 months. During the study, participants will visit the study site 7 times. The study team will: * collect blood and urine samples * check the participants' vital signs * do a physical examination including height and weight * check the participants' heart health by using an electrocardiogram (ECG) * monitor the participants' blood pressure * ask the participants questions about how they are feeling and what adverse events they may be having An adverse event is any problem that happens during the trial. Doctors keep track of all events that happen in trials, even if they do not think the events might be related to the study treatments.

Key facts

Study ID

NCT05254002

Run by

Bayer

People needed

1664

Starts

2022-06-23

Expected to finish

2025-03-17

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant with a clinical diagnosis of chronic kidney disease (CKD) and the following:
• In Part A: eGFR 40-90 ml/min/1.73m\^2 (with no more than 20% having an eGFR >75 ml/min/1.73m\^2) using Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula at screening visit and at least one historical value of eGFR <60 mL/min/1.73 m\^2 within 3 months or have a registered diagnosis of CKD.
• In Part B: eGFR 30-90 ml/min/1.73m\^2 (with no more than 20% having an eGFR >75 ml/min/1.73m\^2) using CKD-EPI formula at screening visit and at least one historical value of eGFR <60 mL/min/1.73 m\^2 within 3 months or have a registered diagnostic of CKD.
• 100 ≤UACR <5000 mg/g at screening visit (mean value from 3 morning void samples) and documentation of albuminuria/proteinuria (quantitative or semi-quantitative measurement) in the participant's medical records at least 3 months prior to screening
• Participant with type 2 diabetes (T2D) as defined by the American Diabetes Association (ADA 2021), with glycated hemoglobin (HbA1c) at screening <11%.
• Participant treated with the clinically maximum tolerated dose, as per investigator judgment, of angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), but not both, for more than 1 month at screening visit.

You may not qualify if…

• Participants with type 1 diabetes (T1D).
• Participant with hepatic insufficiency classified as Child-Pugh C.
• Participant with blood pressure at Day 1 visit (Visit 2) higher than 160 systolic blood pressure (SBP) or 100 diastolic blood pressure (DBP) or SBP lower than 90 mmHg.
• Participant currently treated with a sodium/glucose cotransporter-2 inhibitor (SGLT2i) or SGLT-1/2i or who received a SGLT2i or SGLT-1/2i which cannot be discontinued at least 8 weeks prior to the screening visit and during study intervention treatment.
• Participant treated with another mineralocorticoid receptor antagonist (MRA) (e.g., eplerenone, esaxerenone, spironolactone, canrenone), a renin inhibitor, potassium supplements, a potassium sparing diuretic (e.g., amiloride, triamterene), a potassium binder agent, or angiotensin receptor-neprilysin inhibitor (ARNI) which cannot be discontinued at least 8 weeks prior to the screening visit and during study intervention treatment.
• Participants currently treated or who were treated with Finerenone (Kerendia©) within 8 weeks prior to the screening visit.
• Participant with serum/plasma potassium (K+) above 4.8 mmol/L at screening visit (central laboratory value).

Where it is running

• Academic Medical Research Institute — Los Angeles, California, United States
• Dignity Health Northridge Hospital Medical Center - Nephrology — Northridge, California, United States
• Olive View - UCLA Medical Center — Sylmar, California, United States
• Touro University California - Metabolic Research Center — Vallejo, California, United States
• Florida Kidney Physicians - Delray Beach Nephrology — Delray Beach, Florida, United States
• West Orange Endocrinology & Clinical Research — Ocoee, Florida, United States
• Innovative Research Institute — Port Charlotte, Florida, United States
• Metabolic Research Institute, Inc. — West Palm Beach, Florida, United States
• Grady Memorial Hospital - Endocrinology — Atlanta, Georgia, United States
• Southeast Kidney Associates - East Point — East Point, Georgia, United States
• Velocity Clinical Research - Savannah — Savannah, Georgia, United States
• Nola Care Clinical Research — Metairie, Louisiana, United States
• Omega Clinical Research - Metairie — Metairie, Louisiana, United States
• South Shore Nephrology — Plymouth, Massachusetts, United States
• Lake Michigan Nephrology — Saint Joseph, Michigan, United States
• Oakland Medical Research — Troy, Michigan, United States
• Clinical Research Consultants, a JCCT Company — Kansas City, Missouri, United States
• Kansas City VA Medical Center - Endocrinology — Kansas City, Missouri, United States
• Center for Advanced Medicine - Diabetes Center — St Louis, Missouri, United States
• St. Louis Heart and Vascular, PC - Christian Hospital Office — St Louis, Missouri, United States
• Somnos Clinical Research — Lincoln, Nebraska, United States
• Healor Primary Care / CCT Research — Las Vegas, Nevada, United States
• CCT Research - Santa Rosa Medical Centers of Nevada — Las Vegas, Nevada, United States
• Circuit Clinical/Crystal Run — Middletown, New York, United States
• Southwest Kidney Institute, PLC - Suprise — Surprise, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.